Polfurmetinib

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NamePolfurmetinib
Drug Alias NamePF-07799544ARRY-134
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsHigh-Grade GliomaLow-grade GliomaSolid tumours +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (China) Research And Development Co LtdPfizer Inc
Inactive CompaniesN/A
Active IndicationsHigh-Grade GliomaLow-grade GliomaSolid tumours +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG